Deal Details
Convertible Notes Offering
Summary
Baird served as a co-manager on this offering
About
Natera, Inc. (“Natera” or the “Company”) (NASDAQ-GS:NTRA) recently completed a convertible note offering of $287.5 million 2.25% Convertible Senior Notes due 2027, which includes the full exercise of underwriters’ option to purchase up to an additional $37.5 million of the notes. Natera intends to use a portion of the net proceeds from this offering to repay its obligation under the Term Loan with OrbiMed and the remainder of the net proceeds for working capital and general corporate purposes and development of its product offerings.Natera is a global leader in cell-free DNA testing. The mission of the Company is to change the management of disease worldwide with a focus on reproductive health, oncology and organ transplantation. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The Company offers proprietary genetic testing services to inform physicians who care for pregnant women, oncologists, and cancer researchers, including bio pharmaceutical companies and genetic laboratories through its cloud-based software platform. Natera is headquartered in San Carlos, California.
CONTACT US TO LEARN MORE
- Date
- April 2020
- Company
- Natera, Inc.
- Transaction
- M&A
- Sectors
- Healthcare
- Target Geography
- North America
Share
